Clinical Trials

Administration of HER2 Chimeric Receptor and TGFB Dominant Negative Receptor (DNR) Expressing EBV Specific Lymphocytes for Subjects with Advanced HER2 Positive Lung Malignancy (H-24486) (H-24486)

Administration of HER2 Chimeric Receptor and TGFB Dominant Negative Receptor (DNR) Expressing EBV Specific Lymphocytes for Subjects with Advanced HER2 Positive Lung Malignancy: This study evaluates T cells genetically modified to recognize a protein expressed on some lung cancer cells and to be resistant to TGFB. For more information:http://www.clinicaltrials.gov/ct2/show/NCT00889954